Yi-Chun Chiu

Yi-Chun Chiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi-Chun Chiu has a total of 147 co-authors. Here are the top co-authors by number of shared publications:

  • Seng-Kee Chuah

    Division of Gastroenterology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine Kaohsiung Taiwan

    13 shared publications
  • Chih-Ming Liang

    Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, Taiwan

    10 shared publications
  • Wei-Chen Tai

    Kaohsiung Chang Gung Memorial Hospital

    9 shared publications
  • Keng-Liang Wu

    Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

    8 shared publications
  • Keng-Liang Wu

    Division of Hepatogastroenterology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan

    7 shared publications
  • King-Wah Chiu

    Division of Hepato-gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan

    7 shared publications

Latest Publications

  • Open Access

    Alternation of the oral, gastric and stool microbiome in patients with reflux esophagitis and Barrett's esophagus

    by Chih-Chien Yao, Wei-Chen Tai, Chih-Ming Liang, Ming-Chao Tsai, Yu-Chieh Tsai, Cheng-Kun Wu, Pao-Yuan Huang, Chien-Hung Chen, Yuan-Hung Kuo, Seng-Kee Chuah, et al.


  • Inflammatory Disorders of the Small Intestines

    by Jen-Wei Chou, Chun-Lung Feng, Shang-Fen Huang, Yi-Sing Shih, Shih-Feng Chen, Chun-Fu Ting, Wei-Chen Tai, Ming-Luen Hu, Yi-Chun Chiu, Hsu-Heng Yen, et al.

  • Malignant Neoplasms of the Small Intestines

    by Ming-Luen Hu, Yi-Chun Chiu, Wei-Chen Tai, Hsuan-Ying Huang, Hsu-Heng Yen, Yang-Yuan Chen, Chung-Wei Chen, Ming-Yao Su, Wei-Pin Lin, Cheng-Tang Chiu, et al.

  • Open Access

    FDG PET/CT and Endoscopic Ultrasound for Preoperative T-Staging of Esophageal Squamous Cell Carcinoma

    by Yung-Cheng Huang, Nan-Tsing Chiu, Hung-I Lu, Yi-Chun Chiu, Chien-Chin Hsu, Yu-Ming Wang, Shau-Hsuan Li

    This study aimed to compare the diagnostic performances of endoscopic ultrasound (EUS) and FDG PET/CT in the preoperative T-staging of esophageal squamous cell carcinoma (ESCC) and determine whether their innovative coordination achieves better prediction. In total, 100 patients diagnosed with ESCC, 57 without (CRT[−]sub) and 43 with (CRT[+]sub) neoadjuvant chemoradiotherapy, undergoing EUS and FDG PET/CT, followed by surgical resection of the tumor, were included in this analysis. EUS classified T-stages based on the depth of primary tumor invasion, and FDG PET/CT used thresholded maximal standardized uptake value (SUVmax) classifications. By employing pathology results as the reference standard, we assessed the accuracy of EUS and FDG PET/CT, evaluated their concordance using the κ statistic, and conducted a comparative analysis between the two modalities through McNemar’s chi-square test. FDG PET/CT had higher overall accuracy than EUS (for CRT[−]sub: 71.9%, κ = 0.56 vs. 56.1%, κ = 0.31, p = 0.06; for CRT[+]sub: 65.1%, κ = 0.50 vs. 18.6%, κ = 0.05, p < 0.01) in predicting pT- and ypT-stage. Our proposed method of incorporating both FDG PET/CT and EUS information could achieve higher accuracies in differentiating between early and locally advanced disease in the CRT[−]sub group (82.5%) and determining residual viable tumor in the CRT[+]sub group (83.7%) than FDG PET/CT or EUS alone. FDG PET/CT had a better diagnostic ability than EUS to predict the (y)pT-stage of ESCC. Our complementary method, which combines the advantages of both imaging modalities, can deliver higher accuracy for clinical applications of ESCC.


  • Open Access

    Early and Direct Endoscopic Stone Removal in the Moderate Grade of Acute Cholangitis with Choledocholithiasis Was Safe and Effective: A Prospective Study

    by Chih-Ming Liang, Yi-Chun Chiu, Lung-Sheng Lu, Cheng-Kun Wu, Fai-Meng Sou, Shao-Ming Chiu, Yu-Chi Lee, Pao-Yuan Huang, Seng-Kee Chuah, Chung-Mou Kuo

    Background: Evidence supporting the feasibility of single-stage stone removal in patients with a moderate grade of acute cholangitis remains insufficient. The maximal size of a common bile-duct stone suitable for removal during a single-stage ERCP in a moderate grade of acute cholangitis is unknown. Methods: We prospectively enrolled 196 endoscopic retrograde cholangiopancreatography (ERCP)-naïve patients diagnosed with acute cholangitis and choledocholithiasis. For eligible patients, single-stage treatment involved stone removal at initial ERCP. Results: A total of 123 patients were included in the final analysis. The success rate of complete stone extraction was similar between patients with mild and moderate grades of acute cholangitis (89.2% vs. 95.9%; p = 0. 181). Complication rates were comparable between the two groups. In the moderate grade of the cholangitis group, among patients who underwent early single-stage ERCP, the length of hospitalization declined as short as the patients in the mild grade of cholangitis (10.6 ± 6.2 vs. 10.1 ± 5.1 days; p = 0.408). In the multivariate analysis, early ERCP indicated shorter hospitalization times (≤10 days) (odds ratio (OR), 3.981; p = 0.001). A stone size less than 1.5 cm presented a high success rate (98.0%) for complete stone removal. Conclusions: Single-stage retrograde endoscopic stone removal in mild and moderate grades of acute cholangitis may be safe and effective, which can obviate the requirement for a second session, thus reducing medical expenses. ClinicalTrials.gov: NCT03754491.


  • Open Access

    Risk factors of post‐endoscopic retrograde cholangiopancreatography pancreatitis among living‐donor liver transplant recipients with biliary complications

    by Wendell Espinosa, Yi‐Chun Chiu, Chung‐Mou Kuo, Chih‐Ming Liang, Lung‐Sheng Lu, Cheng‐Kun Wu


  • Open Access

    Incidence of interval colorectal cancer: A tertiary hospital report

    by Wan‐Tz Lai, Shao‐Ming Chiu, Cheng‐Kun Wu, Chih‐Ming Liang, Shih‐Cheng Yang, Chih‐Chien Yao, Chung‐Mou Kuo, Lung‐Sheng Lu, Yi‐Chun Chiu, Keng‐Liang Wu, et al.

    Colorectal cancer (CRC) remains the leading cause of death in Taiwan despite mandatory CRC screening programs for early detection. The development of CRC between periods of follow‐up remains a Taiwanese health and economic burden. This study aimed to investigate the relationship between consequent progression of polyps and interval CRC and identify potential risk factors. This retrospective chart review study reviewed 1671 CRC patients between 1 January 2002 and 31 December 2018, in Kaohsiung Chang Gung Memorial Hospital for interval CRC analysis. Interval CRC is defined as CRC diagnosed within 5 years after a negative colonoscopy. We further analyzed potential risk factors associated with interval CRC such as sex, age, underlying disease, and previous pathologic type of polyps by univariate and multivariate analyses. A total of 44 patients developed interval CRC in this study (2.63%). Ten patients were from the proctologist division and five from the gastroenterology department. Mean diagnostic interval was 919.45 ± 547.78 days in male and 897.87 ± 586.14 days in female patients. Multivariate analysis showed that right‐side colon polyp demonstrated independent risk factors for interval CRC development in our observation (P < .001; hazard ratio (HR), 3.897; 95% confidence interval (CI), 1.934‐7.780). In conclusion, interval CRC prevalence in a cohort is 2.63%. Location of polyps over the right colon is relevant to interval CRC occurrence.

  • Open Access

    Single‐stage retrograde endoscopic common bile duct stone removal might be sufficient in moderate acute cholangitis with a stone size ≤12 mm: A retrospective cohort study with propensity score matching

    by Kuo‐Tung Hung, Chung‐Mou Kuo, Cheng‐En Tsai, Yi‐Chun Chiu, Lung‐Sheng Lu, Cheng‐Kun Wu, Fai‐Meng Sou, Pao‐Yuan Huang, Wei‐Chen Tai, Chung‐Huang Kuo, et al.

    Studies elucidating the efficacy and safety of single‐stage endoscopic treatment for acute moderate cholangitis with choledocholithiasis are limited. Therefore, we performed a retrospective analysis of single‐stage endoscopic treatment for common bile duct (CBD) stone removal in patients with moderate cholangitis to determine the rates of successful stone extraction and complications. A retrospective chart review was conducted for all consecutive patients (n = 632) undergoing endoscopic retrograde cholangiopancreatography (ERCP) for CBD stone removal between January 2010 and September 2013 at the study institution. A total of 346 patients excluded based on the following criteria: procedural failure requiring an anatomy‐modifying operation, stenosis of the pyloric ring, tumor‐related obstruction, treatment requiring only biliary drainage, failure to locate the papilla, intolerance due to inadequate sedation, CBD stone > 12 mm, CBD sludge, and non‐naïve papilla in ERCP. The remaining 286 patients were randomly matched at a 1:2 ratio using propensity score together with age and sex with the Number Cruncher Statistical System statistical software. After propensity score matching, there were 90 and 134 patients in the moderate and no/mild cholangitis groups, respectively. The baseline characteristics and endoscopic findings were comparable between the two groups. The success rate of complete stone extraction was similar between the moderate and no/mild cholangitis groups (90.0% vs 91.0%, P = .793). Additionally, the complication rates were comparable between the moderate and no/mild cholangitis groups (post‐ERCP pancreatitis, 13.3% vs 10.4%, P = .542; pneumonia, 4.4% vs 1.5%, P = .183; perforation, 0% vs 1.5%, P = .243; and mortality, 2.2% vs 0.7%, P = .350). However, there was a trend for higher bleeding rate in the moderate cholangitis group compared with the no/mild cholangitis group (2.2% vs 0%, P = .084). Single‐stage retrograde endoscopic CBD stone removal in patients with moderate cholangitis and choledocholithiasis sized ≤12 mm might be adequate based on the high success rate (90.0%) for stone removal and low complication rates.


  • Open Access

    The efficacy of limited endoscopic sphincterotomy plus endoscopic papillary large balloon dilation for removal of large bile duct stones

    by Chung-Mou Kuo, Yi-Chun Chiu, Chih-Ming Liang, Cheng-Kun Wu, Lung-Sheng Lu, Wei-Chen Tai, Yuan-Hung Kuo, Keng-Liang Wu, Seng-Kee Chuah, Chung-Huang Kuo

    The removal of large bile duct stones (> 15 mm) by conventional endoscopic sphincterotomy (EST) and endoscopic papillary balloon dilation (EPBD) can be challenging, requiring mechanical lithotripsy (ML) in addition to EST or EPBD. The primary complication of ML is basket and stone impaction, which can lead to complications such as pancreatitis and cholangitis. The present study aims to investigate the efficacy of limited EST plus endoscopic papillary large balloon dilation (EST-EPLBD) for large bile duct stone extraction with an extent of cutting < 1/2 the length of the papillary mound. We enrolled 185 patients with ≥15 mm bile duct stones who received EST, EPLBD and limited EST-EPLBD treatment from January 1, 2010 to February 28, 2018, at Kaohsiung Chang Gung Memorial Hospital (Kaohsiung, Taiwan). All patients were categorized into three groups: EST group (n = 31), EPLBD group (n = 96), and limited EST-EPLBD group (n = 58). The primary outcome variables were the success rate of complete stone removal and complications. The limited EST-EPLBD group exhibited a higher success rate of the first-session treatment compared with the EST and EPLBD groups (98.3% vs. 83.9% vs. 86.5%; P = 0.032) but required a longer procedure time (32 (12–61) min vs. 23.5 (17–68) min vs. 25.0 (14–60) min; P = 0.001). The need for ML during the procedure was 4 (12.9%) in the EST group, 10 (10.4%) in the EPLBD group and 2 (3.4%) in the limited EST-EPLBD group. Post-procedure bleeding in the EST group was more common than that in the limited EST-EPLBD group (9.7% vs. 0%; P = 0.038). Furthermore, dilated bile duct was the only risk factor for bile duct stone recurrence in the limited EST-EPLBD group. Limited EST-EPLBD exhibits a higher success rate but requires marginally longer procedure time for the first-session treatment. Furthermore, dilated bile duct is the only risk factor for bile duct stone recurrence in patients undergoing limited EST-EPLBD.